Pharmacotherapy of neurally mediated syncope

Circulation

Volumn 100, Issue 11, 1999, Pages 1242-1248

  Benditt, David G ^a,b   Fahy, Gerard J ^a   Lurie, Keith G ^a   Sakaguchi, Scott ^a   Fabian, William ^a   Samniah, Nemer ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

Cardiovascular Drugs; Nervous system; Pharmacology; Syncope

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIHYDROERGOTAMINE; DISOPYRAMIDE; EPHEDRINE; ETILEPHRINE; FLUDROCORTISONE; METHYLPHENIDATE; METOPROLOL; MIDODRINE; N(G) METHYLARGININE; PINDOLOL; PSEUDOEPHEDRINE; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THEOPHYLLINE; UNCLASSIFIED DRUG; VERLAFAXINE;

ARTICLE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG SOLUBILITY; DRUG TOLERABILITY; FIRST PASS EFFECT; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; NERVOUS SYSTEM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYNCOPE; TACHYPHYLAXIS; TILT TABLE TEST;

EID: 0033554449     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.11.1242     Document Type: Article

References (72)

1. Benditt DG, Sakaguchi S, Sehultz JJ, Remole S, Adler S, Lurie KG. Syncope: diagnostic considerations and the role of tilt table testing. Cardiol Rev. 1993;1:146-156.
2. Kosinski DJ, Grubb BP. Neurally mediated syncope with an update on indications and usefulness of head-up tilt table testing and pharmacologic therapy. Curr Opin Cardiol. 1994;9:53-64.
3. Benditt DG, Goldstein MA, Adler S, Sakaguchi S, Lurie KG. Neurally mediated syncopal syndromes: pathophysiology and clinical evaluation. In: Mandel WJ, ed. Cardiac Arrhythmias. 3rd ed. Philadelphia, Pa: JB Lippincott Co; 1995:879-906.
4. Almquist A, Goldenberg IF, Milstein S, Chen M-Y, Chen X-C, Hansen R, Gornick CC, Benditt DG. Provocation of bradycardia and hypotension by isoproterenol and upright posture in patients with unexplained syncope. N Engl J Med. 1989;320:346-351.
5. Lurie KG, Dutton J, Mangat R, Newman D, Eisenberg S, Scheinman M. Evaluation of edrophonium as a provocative agent for vasovagal syncope during head-up tilt-table testing. Am J Cardiol. 1993;72:1286-1290.
6. Voice RA, Lurie KG, Sakaguchi S, Rector TS, Benditt DG. Comparison of tilt angles and provocative agents (edrophonium and isoproterenol) in improving head-upright tilt table testing. Am J Cardiol. 1998;81: 346-351.
7. Raviele A, Menozzi C, Brignole M, Gasparini G, Alboni P, Musso G, Lolli G, Oddone D, Dinelli M, Mureddu R. Value of head-up tilt testing potentiated with sublingual nitroglycerin to assess the origin of unexplained syncope. Am J Cardiol. 1995;76:267-272.
8. Shen WK, Hammill SC, Munger TM, Stanton M, Packer D, Osborn M, Wood B, Bailey K. Low P, Gersh B. Adenosine: potential modulator for vasovagal syncope. J Am Coll Cardiol. 1996;28:146-154.
9. Brignole M, Gaggioli G, Menozzi C, Gianfranchi L, Bartoletti A, Bottoni N, Lolli G, Oddone D, Del Rosso A, Pellinghelli G. Adenosine-induced atrioventricular block in patients with unexplained syncope: the diagnostic value of ATP testing. Circulation. 1997;96:3921-3927.
10. Flammang D, Church T, Waynberger M, Chassing A, Antiel M. Can adenosine 5′-triphosphate be used to select treatment in severe vasovagal syndrome? Circulation. 1997;96:1201-1208.
11. Sheldon RS, Gent M, Roberts RS, Connolly SJ, on behalf of the NAVPAC Investigators. North American Vasovagal Pacemaker Study: study design and organization. Pacing Clin Electrophysiol. 1997;20: 844-848.
12. Connolly SJ, Sheldon R, Roberts RS, Gent M. The North American vasovagal pacemaker study (VPS): a randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol. 1999;33:16-20.
13. Benditt DG. Cardiac pacing for prevention of vasovagal syncope. J Am Coll Cardiol. 1999;33:21-23.
14. Chosy JJ, Graham DT. Catecholamines in vasovagal fainting. J Psychosom Res. 1965;9:189-194.
15. Vingerhoets AJJM. Biochemical changes in two subjects succumbing to syncope. Psychosom Med. 1984;46:95-103.
16. Fitzpatrick A, Williams T, Ahmed R, Lightman S, Bloom SR, Sutton R. Echocardiographic and endocrine changes during vasovagal syncope induced by prolonged head-up tilt. Eur J Cardiac Pacing Electrophysiol. 1992;2:121-128.
17. Muscholl E. Peripheral muscarinic control of norepinephrine release in the cardiovascular system. Am J Physiol. 1980;239:H713-H720.
18. Levy MN. Cardiac sympathetic-parasympathetic interactions. Fed Proc. 1984;43:2598-2602.
19. Asso A, Milstein S, Dunnigan A, Remole S, Bailin S, Benditt DG. Prognostic significance of parenteral metoprolol during head-up tilt testing. Circulation. 1991;84(suppl II):II-409. Abstract.
20. Muller G, Deal B, Strasburger JF, Benson DW Jr. Usefulness of metoprolol for unexplained syncope and positive response to tilt testing in young persons. Am J Cardiol. 1993;71:592-595.
21. Sra JS, Murthy VS, Jazayeri MR, Shen Y-H, Troup P, Avitall B, Akhtar M. Use of intravenous esmolol to predict efficacy of oral adrenergic blocker therapy in patients with neurocardiogenic syncope. J Am Coll Cardiol. 1993;19:402-408.
22. Lurie KG, Dutton J, Mangat R, Scheinman MM. Pindolol is effective in patients with vasovagal syncope. Pacing Clin Electrophysiol. 1992; 15:592. Abstract.
23. Fitzpatrick AP, Ahmed R, Williams S, Sutton R. A randomised trial of medical therapy in "malignant vasovagal syndrome" or "neurally-mediated bradycardia hypotension syndrome." Eur J Cardiac Pacing Electrophysiol. 1991;2:99-102.
24. Brignole M, Menozzi C, Gianfranchi L, Lolli G, Bottoni N, Oddone D. A controlled trial of acute and long-term medical therapy in tilt-induced neurally-mediated syncope. Am J Cardiol. 1992;70:339-342.
25. Mahanonda N, Bhuripanyo K, Kangkagate C, Wansanit K, Kulchot B, Nademanee K, Chaithiraphan S. Randomized double-blind placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table results. Am Heart J. 1995;130:1250-1253.
26. Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med. 1982;307:997-999.
27. Milstein S, Buetikofer J, Dunnigan A, Benditt DG, Gornick C, Reyes WJ. Usefulness of disopyramide for prevention of upright tilt-induced hypotension-bradycardia. Am J Cardiol 1990;65:1339-1344.
28. Morillo C, Leitch JW, Yee R, Klein GJ. A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally mediated syncope induced by head-up tilt. J Am Coll Cardiol. 1993;22:1843-1848.
29. Kelly PA, Mann DE, Adler SW, Fuenzalida CE, Reiter MJ. Low dose disopyramide often fails to prevent neurogenic syncope during head-up tilt testing. Pacing Clin Electrophysiol. 1994;17:573-576.
30. Grubb BP, Temesy-Armos P, Hahn H, Elliott L. Utility of upright tilt-table testing in the evaluation and management of syncope of unknown origin. Am J Med. 1991;90:6-10.
31. Sra JS, Jazayeri MR, Avitall B, Dhala A, Deshpande S, Blanck Z, Akhtar M. Comparison of cardiac pacing with drug therapy in the treatment of neurocardiogenic (vasovagal) syncope with bradycardia or asystole. N Engl J Med. 1993;328:1085-1090.
32. Kosinski DJ, Grubb BP, Temesy-Armos PN. The use of serotonin re-uptake inhibitors in the treatment of neurally mediated cardiovascular disorders. J Serotonin Res. 1994;1:85-90.
33. Gonzalez-Heydrich J, Peroutka SJ. Serotonin receptor and reuptake sites: pharmacologic significance. J Clin Psychiatry. 1990;51(suppl 4):5-12.
34. Smith ML, Carlson MD, Thames MC. Naloxone does not prevent vasovagal syncope during simulated orthostasis in humans. J Auton Nerv System. 1993;45:1-9.
35. Kosinski D, Grubb BP, Temesy-Armos P. The use of serotonin reuptake inhibitors in the treatment of neurally mediated cardiovascular disorders. J Serotonin Res. 1994;1:85-90.
36. Morgan DA, Thoren P, Wilczynski EA, Victor RG, Mark AL. Serotoninergic mechanisms mediate renal sympathoinhibition during severe hemorrhage in rats. Am J Physiol. 1988;255:H496-H502.
37. Kosinski D, Grubb B, Temesy-Armos P. Pathophysiological aspects of neurocardiogenic syncope: current concepts and new perspectives. Pacing Clin Electrophysiol. 1995;18:716-724.
38. Grubb BP, Wolfe D, Samoil D, Temesy-Armos P, Hahn H, Elliott L. Usefulness of fluoxetine hydrochloride for prevention of resistant upright tilt induced syncope. Pacing Clin Electrophysiol. 1993;16:458-464.
39. Grubb BP, Kosinski D. Current trends in etiology, diagnosis, and management of neurocardiogenic syncope. Curr Opin Cardiol. 1996;11: 32-41.
40. Grubb BP, Samoil D, Kosinski D, Temesy-Armos P, Akpunonu B. The use of serotonin reuptake inhibitors for the treatment of carotid sinus hypersensitivity syndrome unresponsive to dual chamber pacing. Pacing Clin Electrophysiol. 1994;17:1434-1436.
41. Almquist A, Gornick CC, Benson DW Jr, Dunnigan A, Benditt DG. Carotid sinus hypersensitivity: evaluation of the vasodepressor component. Circulation. 1985;67:927-936.
42. Sutton R, Brignole M, Raviele A, for the Vasis Group Investigators. Randomised controlled trial of etilephrine therapy for vasovagal syncope. Arch Mal Coeur. 1998;91(special III):242. Abstract.
43. Gilden JL. Midodrine in neurogenic orthostatic hypotension. Int Angiol. 1993;12:125-131.
44. Low PA, Gilden JL, Freeman R, Sheng K-N, McElligott MA. Efficacy of midrodrine vs placebo in neurogenic orthostatic hypotension. JAMA. 1997;13:1046-1051.
45. Sra J, Maglio C, Biehl M, Dhala A, Blanck Z, Deshpande S, Jazayeri MR, Akhtar M. Efficacy of midodrine hydrochloride in neurocardiogenic syncope refractory to standard therapy. J Cardiovasc Electrophysiol. 1997;8:42-46.
46. Benditt DG, Samniah N, Sakaguchi S, Fahy G, Wilbert L. Midodrine is effective in patients with refractory neurally-mediated syncope. Circulation. 1998;98:17(suppl I):I-706. Abstract.
47. Scott WA, Pongiglione G, Bromberg BI, Schaffer MS, Deal BJ, Fish FA, Dick M. Randomized comparison of atenolol and fludrocortisone acetate in the treatment of pediatric neurally mediated syncope. Am J Cardiol. 1995;76:400-402.
48. Benditt DG, Benson DW Jr, Kriett JM, Dunnigan A, Pritzker MR, Crouse L, Scheinman MM. Electrophysiologic effects of theophylline in young patients with recurrent symptomatic bradyarrhythmias. Am J Cardiol. 1983;52:1223-1229.
49. Nelson S, Stanley M, Love CJ, Coyne KS, Schaal SF. Autonomic and hemodynamic effects of oral theophylline in patients with vasodepressor syncope. Arch Intern Med. 1991;151:2425-2429.
50. Sander-Jensen K, Secher NH, Astrup A, Christensen NJ, Giese J, Schwanz TW, Warberg J, Bie P. Hypotension induced by passive head-up tilt: endocrine and circulatory mechanisms. Am J Physiol. 1986; 251:R742-R748.
51. Fitzpatrick A, Williams T, Jeffrey C, Lightman S, Sutton R. Pathogenic role for arginine vasopressin (AVP) and catecholamines (EP & NEP) in vasovagal syncope. J Am Coll Cardiol. 1990;15:98. Abstract.
52. Perna GP, Ficola U, Salvatori MP, Stanislao M, Vigna C, Villella A, Russo A, Fernelli R, Vittori PGP, Loperfido F. Increase of plasma beta endorphins in vasodepressor syncope. Am J Cardiol. 1990;65:929-930.
53. Faden AI, Jacobs TP, Holaday JW. Opiate antagonist improves neurologic recovery after spinal injury. Science. 1981;211:493-494.
54. Rutter PC, Potocnik SJ, Ludbrook J. Sympathoadrenal mechanisms in cardiovascular responses to naloxone after hemorrhage. Am J Physiol. 1987;252:H40-H46.
55. G-Methyl-L-arginine, an inhibitor of L-arginine-derived nitric oxide synthesis, stimulates renal sympathetic nerve activity in vivo: a role for nitric oxide in the central regulation of sympathetic tone? Circ Res. 1992;70:607-611.
56. Kaufmann H, Berman J, Oribe E, Oliver J. Possible increases in EDRF/NO in neurally mediated syncope, Clin Auton Res. 1993;3:77. Abstract.
57. Dietz NM, Rivera JM, Eggener SE, Fix RT, Warner DO, Joyner MJ. Nitric oxide contributes to the rise in forearm blood flow during mental stress in humans. J Physiol (Lond). 1994;480:361-368.
58. Dietz NM, Joyner MJ, Shepherd JT. Vasovagal syncope and skeletal muscle vasodilatation: the continuing conundrum. Pacing Clin Electrophysiol. (suppl). In press.
59. Abi-Samra F, Maloney JD, Fouad-Tarazi FM, Castle L. The usefulness of head-up tilt testing and hemodynamic investigations in the workup of syncope of unknown origin. Pacing Clin Electrophysiol. 1988;11: 1202-1214.
60. Blanc JJ, Genet L, Mansourati J, Forneiro I, Corbel C, Pennec Y, Mottier D. Interet du test d'inclinaison dans le diagnostic etiologique des pertes de connaissance. Presse Med. 1990;19:857-859.
61. Sra JS, Anderson AF, Sheikh SH, Avitall B, Tchou PJ, Troup PJ, Gilbert CJ, Akhtar M. Unexplained syncope evaluated by electrophysiologic studies and head-up tilt testing. Ann Intern Med. 1991;114:1013-1019.
62. Natale A, Sra J, Dhala A, Wase A, Jazayeri M, Deshpande S, Blanck Z, Akhtar M. Efficacy of different treatment strategies for neurocardiogenic syncope. Pacing Clin Electrophysiol. 1995;18:655-662.
63. Benditt DG, Ferguson DW, Grubb BP, Kapoor WN, Kugler J, Lerman BB, Maloney JD, Raviele A, Sutton R, Wolk MJ, Wood DL. Tilt-table testing for assessing syncope: an American College of Cardiology expert consensus document. J Am Coll Cardiol. 1996;28:263-275.
64. Moya A, Permanyer-Miralda, Sagrista J, Rius T. Is there a role for tilt testing in the evaluation of treatment of vasovagal syncope? In: Blanc J-J, Benditt DG, Sutton R, eds. Neurally-Mediated Syncope: Pathophysiology, Investigations, Treatment. Armonk, NY: Futura Publishing Co; 1996:107-111.
65. Moya A, Permanyer-Miralda G, Sagrista-Sauleda J, Came X, Rius T, Mont L, Soler-Soler J. Limitations of head-up tilt test for evaluating the efficacy of therapeutic interventions in patients with vasovagal syncope: results of a controlled study of etilefrine versus placebo. J Am Coll Cardiol. 1995;25:65-69.
66. Raviele A, Gasparini G, DiPede F, Delise P, Bonso A, Piccolo E. Usefulness of head-up tilt test in evaluating patients with syncope of unknown origin and negative electrophysiologic study. Am J Cardiol. 1990;65:1322-1327.
67. Grubb BP, Gerard G, Roush K, Temesy-Armos P, Elliott L, Hahn H, Spann C. Differentiation of convulsive syncope and epilepsy with head-up tilt testing. Ann Intern Med. 1991;115:871-876.
68. Strieper MJ, Campbell RM. Efficacy of apha-adrenergic agonist therapy for prevention of pediatric neurocardiogenic syncope. J Am Coll Cardiol. 1993;22:594-597.
69. Cox MM, Perlman BA, Mayor MR, Silberstein T, Levin E, Pringle L, Castellanos A, Myerburg R. Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope. J Am Coll Cardiol. 1995;26:1293-1298.
70. Grubb BP, Wolfe D, Samoil D, Madu E, Temesy-Armos P, Hahn H, Elliott L. Recurrent unexplained syncope in the elderly: the use of head-upright tilt table testing in evaluation and management. J Am Geriat Soc. 1992;40:1123-1128.
71. Sra JS, Anderson AF, Sheikh SH, Avitall B, Tchou PJ, Troup PJ, Gilbert CJ, Akhtar M. Unexplained syncope evaluated by electrophysiologic studies and head-up tilt testing. Ann Intern Med. 1991;114:1013-1019.
72. Grubb BP, Temesy-Armos P, Moore J, Wolfe D, Hahn H, Elliott L. Head-upright tilt-table testing in evaluation and management of the malignant vasovagal syndrome. Am J Cardiol. 1992;69:904-908.